{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:45:42Z","timestamp":1793303142986,"version":"4.5.0"},"reference-count":38,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Youth Beijing Scholar Program","award":["010"],"award-info":[{"award-number":["010"]}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2017YFC1307900"],"award-info":[{"award-number":["2017YFC1307900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2017YFC1307905"],"award-info":[{"award-number":["2017YFC1307905"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"\"National Ten-Thousand Talent Plan\"- Leadership of Scientific and Technological Innovation"},{"name":"Beijing Talent Project - Class A: Innovation and Development","award":["2018A12"],"award-info":[{"award-number":["2018A12"]}]},{"name":"Beijing Jialin Pharmaceutical Co. LTD"},{"name":"Beijing Outstanding Young Scientist Program","award":["BJJWZYJH01201910025030"],"award-info":[{"award-number":["BJJWZYJH01201910025030"]}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81825007"],"award-info":[{"award-number":["81825007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Stroke Vasc Neurol"],"accepted":{"date-parts":[[2023,1,8]]},"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>It remains unclear if intensive antiplatelet and statin treatments begun within 24\u201372\u2009hours of cerebral ischaemic events from intracranial or extracranial atherosclerosis is effective or safe.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The Intensive Statin and Antiplatelet Therapy for High-risk Intracranial or Extracranial Atherosclerosis (INSPIRES) trial is a randomised, double-blind, placebo-controlled, multicentre and 2\u00d72 factorial trial. 6100 individuals between the ages of 35 and 80 who have experienced a mild ischaemic stroke or high-risk transient ischaemic attack (TIA) within the previous 72 hours that is attributed to \u226550% atherosclerotic stenosis of a major intracranial or extracranial artery or multiple infarctions of atherosclerotic origin will be enrolled in the trial. Eligible subjects will be randomised 1:1:1:1 to one of four groups: (1) intensive antiplatelet therapy (combined clopidogrel and aspirin for days 1\u201321, then aspirin placebo and clopidogrel for days 22\u201390) plus immediate intensive statin therapy(atorvastatin at a dose of 80\u2009mg daily for the first 21 days, then 40\u2009mg daily for days 22\u201390); (2) intensive antiplatelet therapy plus delayed intensive statin therapy (atorvastatin placebo for days 1\u20133, followed by 40\u2009mg per day of atorvastatin for days 4\u201390); (3) standard antiplatelet therapy (combination of clopidogrel placebo with aspirin for 90 days) plus immediate intensive statin therapy and (4) standard antiplatelet therapy plus delayed intensive statin therapy. The primary efficacy endpoint is any new stroke (ischaemic or haemorrhagic) within 90 days after randomisation. The primary safety endpoint is moderate to severe bleeding at 90 days.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The INSPIRES trial will assess the efficacy and safety of intensive antiplatelet therapy and immediate intensive statin therapy begun within 72 hours of onset in decreasing the recurrent stroke at 90 days in patients with acute mild ischaemic stroke or high-risk TIA of intracranial or extracranial atherosclerosis origin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03635749\">NCT03635749<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/svn-2022-002084","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T10:30:25Z","timestamp":1674815425000},"page":"249-258","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":33,"title":["Rationale and design of a randomised double-blind 2\u00d72 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclerosis (INSPIRES)"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct03635749","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03635749","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ying","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuesong","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2608-484X","authenticated-orcid":false,"given":"Shangrong","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2551-9314","authenticated-orcid":false,"given":"Weiqi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9431-9925","authenticated-orcid":false,"given":"Yingying","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3809-2209","authenticated-orcid":false,"given":"Tingting","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4918-0845","authenticated-orcid":false,"given":"Xia","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8345-5147","authenticated-orcid":false,"given":"Xingquan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8591-4105","authenticated-orcid":false,"given":"Hao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2912-0714","authenticated-orcid":false,"given":"S Claiborne","family":"Johnston","sequence":"additional","affiliation":[{"name":"Dean's Office, Dell Medical School, University of Texas at Austin, Austin, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Amarenco","sequence":"additional","affiliation":[{"name":"Department of Neurology and Stroke Center, Assistance Publique-H\u00f4pitaux de Paris (APHP), Bichat Hospital, INSERM LVTS-U1148, University of Paris, Paris, France"},{"name":"Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2734-5132","authenticated-orcid":false,"given":"Philip M","family":"Bath","sequence":"additional","affiliation":[{"name":"Stroke Trials Unit, Mental Health & Clinical Neuroscience, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9976-2341","authenticated-orcid":false,"given":"Yongjun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"},{"name":"National Center for Neurological Diseases, Beijing, China"},{"name":"Research Unit of Artificial Intelligence in Cerebrovascular Disease, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3267-0039","authenticated-orcid":false,"given":"Yilong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"},{"name":"National Center for Neurological Diseases, Beijing, China"},{"name":"Chinese Institute for Brain Research, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"2025082410482636000_8.3.249.1","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000211"},{"key":"2025082410482636000_8.3.249.2","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/jamaneurol.2021.2440","article-title":"Efficacy and safety of ticagrelor and aspirin in patients with moderate ischemic stroke: an exploratory analysis of the THALES randomized clinical trial","volume":"78","author":"Wang","year":"2021","journal-title":"JAMA Neurol"},{"key":"2025082410482636000_8.3.249.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916870"},{"key":"2025082410482636000_8.3.249.4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.003187"},{"key":"2025082410482636000_8.3.249.5","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/CIRCULATIONAHA.119.040713","article-title":"Time course for benefit and risk of clopidogrel and aspirin after acute transient ischemic attack and minor ischemic stroke","volume":"140","author":"Johnston","year":"2019","journal-title":"Circulation"},{"key":"2025082410482636000_8.3.249.6","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000375"},{"key":"2025082410482636000_8.3.249.7","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10555"},{"key":"2025082410482636000_8.3.249.8","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2002.3236"},{"key":"2025082410482636000_8.3.249.9","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.32.4.980"},{"key":"2025082410482636000_8.3.249.10","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000044458.23905.3B"},{"key":"2025082410482636000_8.3.249.11","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.110.596734"},{"key":"2025082410482636000_8.3.249.12","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000269789.09277.47"},{"key":"2025082410482636000_8.3.249.13","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.117.017623"},{"key":"2025082410482636000_8.3.249.14","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.116.014600"},{"key":"2025082410482636000_8.3.249.15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.5853\/jos.2015.01578","article-title":"Effect and safety of rosuvastatin in acute ischemic stroke","volume":"18","author":"Heo","year":"2016","journal-title":"J Stroke"},{"key":"2025082410482636000_8.3.249.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043033"},{"key":"2025082410482636000_8.3.249.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108153250701"},{"key":"2025082410482636000_8.3.249.18","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1212\/01.WNL.0000140490.22251.B6","article-title":"Multiple acute cerebral infarcts on diffusion-weighted imaging and risk of recurrent stroke","volume":"63","author":"Wen","year":"2004","journal-title":"Neurology"},{"key":"2025082410482636000_8.3.249.19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jamaneurol.2018.0247","article-title":"Dual antiplatelet therapy in transient ischemic attack and minor stroke with different infarction patterns: subgroup analysis of the chance randomized clinical trial","volume":"75","author":"Jing","year":"2018","journal-title":"JAMA Neurol"},{"key":"2025082410482636000_8.3.249.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215340"},{"key":"2025082410482636000_8.3.249.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-021-01388-6","article-title":"Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trials","volume":"21","author":"Woodhouse","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"2025082410482636000_8.3.249.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309023291001"},{"key":"2025082410482636000_8.3.249.23","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001972"},{"key":"2025082410482636000_8.3.249.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105335"},{"key":"2025082410482636000_8.3.249.25","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1001\/jamaneurol.2015.4315","article-title":"Factors associated with recurrent ischemic stroke in the medical group of the SAMMPRIS trial","volume":"73","author":"Waters","year":"2016","journal-title":"JAMA Neurol"},{"key":"2025082410482636000_8.3.249.26","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2020-000538"},{"key":"2025082410482636000_8.3.249.27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1693"},{"key":"2025082410482636000_8.3.249.28","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00017-4"},{"key":"2025082410482636000_8.3.249.29","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.120.032239"},{"key":"2025082410482636000_8.3.249.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111749"},{"key":"2025082410482636000_8.3.249.31","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1910355","article-title":"A comparison of two LDL cholesterol targets after ischemic stroke","volume":"382","author":"Amarenco","year":"2020","journal-title":"N Engl J Med"},{"key":"2025082410482636000_8.3.249.32","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1161\/STROKEAHA.122.039728","article-title":"Yield of dual therapy with statin and ezetimibe in the treat stroke to target trial","volume":"53","author":"Amarenco","year":"2022","journal-title":"Stroke"},{"key":"2025082410482636000_8.3.249.33","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1212\/WNL.0000000000002493","article-title":"Statin pretreatment is associated with better outcomes in large artery atherosclerotic stroke","volume":"86","author":"Tsivgoulis","year":"2016","journal-title":"Neurology"},{"key":"2025082410482636000_8.3.249.34","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.111.627729"},{"key":"2025082410482636000_8.3.249.35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2018.08.040","article-title":"Optimising treatment of hyperlipidaemia: quantitative evaluation of UK, USA and european guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk","volume":"278","author":"Soran","year":"2018","journal-title":"Atherosclerosis"},{"key":"2025082410482636000_8.3.249.36","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht055"},{"key":"2025082410482636000_8.3.249.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"2025082410482636000_8.3.249.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801174"}],"container-title":["Stroke and Vascular Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/svn-2022-002084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T17:48:36Z","timestamp":1756057716000},"score":1,"resource":{"primary":{"URL":"https:\/\/svn.bmj.com\/lookup\/doi\/10.1136\/svn-2022-002084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,6,23]]},"published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1136\/svn-2022-002084"],"URL":"https:\/\/doi.org\/10.1136\/svn-2022-002084","relation":{},"ISSN":["2059-8688","2059-8696"],"issn-type":[{"value":"2059-8688","type":"print"},{"value":"2059-8696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]}}}